New FDA guidance on the use of Bayesian statistics signals a broader shift in accommodating more flexible clinical trial designs and the complexities of diseases such as certain cancers and rare disorders, which may lead to more efficient trials, lower development costs, and faster innovation.
The post The FDA’s Bayesian Guidance Could Quietly Reshape Clinical Trial Design appeared first on MedCity News.
